Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may replace brain scans for Alzheimer's drug monitoring

NCT ID NCT07153848

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study will follow 400 people with early Alzheimer's who are taking the drug lecanemab. Researchers want to see if simple blood tests can detect whether the drug is reducing amyloid plaques in the brain, which is currently measured with expensive PET scans. The goal is to find a cheaper, easier way to monitor treatment effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lecanemab
What this could lead to
If successful, this study could show that simple blood tests can track whether lecanemab is clearing amyloid plaques from the brain, potentially reducing the need for expensive PET scans.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. The results may not apply to all Alzheimer's patients, and blood biomarkers may not reliably match brain changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Samples from a multicenter study cohort of early AD in Zhejiang Province (real-world study based on lencanumab treatment)

Ages

45 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria (all of the following must be met simultaneously): Mild Alzheimer's Disease (AD): 1. Age ≥ 45 years but ≤ 85 years; 2. Literacy level of elementary school and above (i.e., ≥3 years of education); 3. Fulfillment of the diagnostic criteria for probable AD in the NINCDS-ADRDA 2007 revision (or the diagnostic criteria for clinically probable AD in the National Institute on Aging and Alzheimer's Disease Association NIA-AA 2011 edition); 4. Clinical Dementia Rating Scale CDR-global = 1 point; 5. Aβ-PET scan suggesting extensive deposition of Aβ plaques in the brain. AD-derived mild cognitive impairment (aMCI) inclusion criteria (must meet all of the following conditions at the same time): 1. Age: 45 years or older but ≤85 years; 2. Literacy level elementary school and above (i.e., ≥3 years of education); 3. Meeting Peterson's 2004 diagnostic criteria for MCI: (i) Complaint of memory impairment that can be confirmed by an informed person; (ii) objective evidence of memory impairment (memory test scores 1-1.5 standard deviations below normal controls matched for age and literacy; e.g., Huashan Hospital's recommended cut-off values for those with elementary school literacy or above are as follows: long-delayed recall 50-59 years old ≤ 5, 60-69 years old ≤ 4, 70-79 years old ≤ 3, 80-89 years old ≤ 2, or re-recognition scores of 50-59 years old ≤ 20, 60-69 age ≤19 points, 70-79 years ≤18 points, 80-89 years ≤16 points); (iii) Overall cognitive functioning was largely preserved, with CDR-global = 0.5 points and MMSE: ≥24 points for those with junior high school or higher education used in this study; ④ Daily life ability remains normal (basically able to complete going out by transportation and shopping and counting, etc.); ⑤ Does not meet the International Classification of Diseases Diagnostic Manual, 10th edition dementia criteria (for research purposes) and the National Institute of Neurological and Speech-Language Disorders and Stroke, Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) likely diagnostic criteria for AD dementia; (vi) Aβ-PET scan suggested extensive deposition of Aβ plaques in the brain. Normal control Inclusion criteria (all of the following must be met simultaneously). 1. Age ≥55 years but ≤85 years; 2. Elementary school 3 years of education and above; 3. MMSE: ≥26 points for those with junior high school or higher education; 4. CDR=0; 5. Activity of Daily Living Scale (ADL) score ≤ 20; 6. No significant deposition of Abeta in the brain as indicated by Aβ-PET scan. Exclusion Criteria (excluded if any of the following conditions were met): 1. Those with a history of stroke and neurologic focal signs, head MRI scans excluding external infarct foci, brain softening foci and other occupying lesions, etc., as well as SWI sequences showing 5 or more microhemorrhagic foci, vascular malformations, etc; 2. Presence of other neurological disorders that may cause brain dysfunction (e.g., schizophrenia, severe anxiety and depression, frontotemporal lobe dementia, Huntington's disease, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, and normal cranial pressure hydrocephalus, etc.); 3. Presence of other systemic diseases that can cause cognitive impairment, such as hypothyroidism, folic acid and vitamin B12 deficiency, specific infections (e.g., syphilis, HIV), alcohol and drug abuse; 4. Presence of a history of severe hepatic or renal insufficiency, severe pulmonary insufficiency, severe anemia, severe gastrointestinal disorders, severe cardiac arrhythmias, cardiac infarction within 6 months, and malignant tumors; 5. Oral anticoagulants (including warfarin and new oral anticoagulants, etc.); 6. Presence of contraindications to NMR such as metal implantation in the body; 7. Diseases such as aphasia, impaired consciousness, etc. that prevent cooperation in completing the cognitive examination; 8. Refusal to sign the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • The First Affiliated Hospital of Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.